Nanoemulsions Global Strategic Business Report 2024-2030: Analysis and Forecasts by Steroids, Anesthetics, NSAIDs, Immunosuppressant, Antiretroviral, Antimicrobials, Vasodilators – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nanoemulsions – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Nanoemulsions was estimated at US$12.1 Billion in 2023 and is projected to reach US$20.6 Billion by 2030, growing at a CAGR of 7.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market … [Read more…]

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) results from the pivotal Phase 3 TALAPRO-2 trial of TALZENNA® in combination with XTANDI® in patients with metastatic castration-resistant prostate cancer (mCRPC) Updated analysis from the Phase 3 … [Read more…]

Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer

– Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer in the first-line setting – – Primary analysis showed the Itovebi-based regimen reached statistical significance, more than doubling progression-free survival in this patient population – … [Read more…]

Oasis Initiates Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors (Securities Code: 4967 JT)

*Oasis initiates shareholder derivative lawsuit after Kobayashi Pharma’s Company Auditors choose not to file *Oasis submitted a request to Kobayashi Pharma Auditors to commence legal action against its Directors on Nov. 20, 2024 *Oasis estimates that damages incurred by Kobayashi Pharma due to Directors’ breach of duties total approx. JPY 11 billion HONG KONG–(BUSINESS WIRE)–Oasis … [Read more…]

ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi Sankyo and AstraZeneca’s ENHERTU to an earlier HR positive treatment setting and broadens the patient population eligible for treatment with a HER2 directed therapy to those with HER2 … [Read more…]

Insight Health Joins athenahealth’s Marketplace Program to Introduce AI Clinical Assistant to Healthcare Providers

Insight Health’s AI agents automate clinical documentation and save providers two hours daily AUSTIN, Texas–(BUSINESS WIRE)–Insight Health AI, Inc., a provider of AI-powered clinical documentation and virtual care solutions, today announced an agreement with athenahealth, Inc. through the company’s award-winning athenahealth® Marketplace program. Now available to athenahealth’s growing network of healthcare providers, the newly integrated … [Read more…]

Ovarian Cancer Market Expected to Skyrocket to USD 31.31 Billion by 2034, Driven by Advances in Detection and Treatment – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region” report has been added to ResearchAndMarkets.com’s offering. The comprehensive analysis of the global ovarian cancer market reveals a promising trajectory for the industry, with projections estimating a compound annual growth rate (CAGR) of 23.53% over the forecast period … [Read more…]

Molecular Switches as Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application Market Research Report 2025 with Top 20 Drugs Sales Targeting Molecular Switches 2022-2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Molecular Switches As Therapeutic Targets, Drug Development, Drug Delivery Mechanism & Application By Indications Insight 2025” report has been added to ResearchAndMarkets.com’s offering. Molecular switches are dynamic entities capable of transitioning between distinct states in response to specific environmental or biological triggers. These triggers can include changes in pH, light exposure, temperature, redox … [Read more…]

FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)

Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy in the U.S. for eligible patients with advanced PPGL RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, … [Read more…]

Olink® Reveal Seamlessly Connects Genomics and Proteomics, Empowering Researchers to Uncover the Dynamic Mechanisms Underlying Biology

New next generation sequencing-based proteomics kits designed to integrate with multiple NGS platforms, eliminating the need for new instrumentation or specialized expertise UPPSALA, Sweden–(BUSINESS WIRE)–Thermo Fisher Scientific, the world leader in serving science, today announced the introduction of Olink® Reveal, setting a new standard for affordable, high-plex proteomics that enables researchers to identify circulating biomarkers … [Read more…]